Work

A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps2670

Authors: Ecaterina Elena Dumbrava, Kerry Culm, Lukas Makris, Melissa Lynne Johnson, David Sommerhalder, Jason Timothy Henry, Anna Rachel Minchom, Elena Garralda Cabanas, Min Yang, Monette Cotreau, Anne-Laure Goenaga, Dalia Burzyn, Zhi-Yong Yang, Ronnie Wei, John Mascola, Giovanni Abbadessa, Gary Nabel

Institutions: The University of Texas MD Anderson Cancer Center, OPKO Health (United States), Sarah Cannon, HealthONE, Royal Marsden NHS Foundation Trust, Institute of Cancer Research

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410809767

Cites:

Cited by: 1

Related to: 10